Drug Profile
Cetuximab biosimilar - Celltrion
Alternative Names: CT P15Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Celltrion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 20 Feb 2015 No development reported in Colorectal cancer in South Korea (unspecified route) (Celltrion financial report, June 2015)